Bright Uro is a technology company.
Bright Uro has raised $4.0M across 1 funding round.
Bright Uro has raised $4.0M in total across 1 funding round.
Bright Uro has raised $4.0M in total across 1 funding round.
Bright Uro's investors include Johnson & Johnson Innovation, Sonder Capital.
Bright Uro is a medical technology company that develops a wireless, catheter-free urodynamics system called the Glean Urodynamics System, designed for non-invasive bladder function monitoring. It serves urologists, urogynecologists, and healthcare professionals by providing a more comfortable, accurate, and streamlined alternative to traditional invasive catheter-based urodynamic testing. This innovation improves patient experience, expands access to testing in standard clinical exam rooms, and enhances diagnostic accuracy for lower urinary tract symptoms (LUTS) such as urinary incontinence and overactive bladder[1][2][4].
Founded in 2021, Bright Uro emerged from foundational research at Cleveland Clinic, with its CEO Derek Herrera leading the company. The idea originated to address the discomfort, infection risks, and diagnostic limitations of conventional urodynamic studies. Early traction includes FDA clearance of the Glean system and partnerships with leading institutions like Cleveland Clinic and Laborie Medical Technologies, which invested in Bright Uro to accelerate its market impact[2][3][4].
Bright Uro rides the trend toward minimally invasive, patient-centric medical diagnostics enhanced by digital health and cloud technologies. The timing is critical as the aging population increases demand for better management of LUTS, affecting millions, especially older adults. Market forces favor innovations that reduce healthcare costs, improve patient comfort, and provide more reliable physiological data. Bright Uro’s technology influences the broader urology ecosystem by setting new standards for ambulatory urodynamics and enabling more personalized, data-driven care[3][4].
Bright Uro is poised for growth as it expands clinical adoption and integrates advanced data science into its platform. Future trends shaping its journey include the rise of remote patient monitoring, AI-driven diagnostics, and increasing emphasis on outpatient care models. Its influence is likely to evolve from a disruptive startup to a key player in urology diagnostics, potentially broadening into related fields such as urogynecology and chronic bladder condition management. Continued partnerships with major medical institutions and technology investors will support its mission to transform LUTS care globally[3][4][5].
Bright Uro has raised $4.0M across 1 funding round. Most recently, it raised $4.0M Seed in June 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2022 | $4.0M Seed | Johnson & Johnson Innovation, Sonder Capital |